intuitive surgical inc. - ISRG
ISRG
Close Chg Chg %
476.32 11.83 2.48%
Closed Market
488.15
+11.83 (2.48%)
Volume: 2.52M
Last Updated:
Feb 6, 2026, 4:00 PM EDT
Company Overview: intuitive surgical inc. - ISRG
ISRG Key Data
| Open $481.43 | Day Range 480.07 - 491.65 |
| 52 Week Range 425.27 - 609.08 | Market Cap $169.93B |
| Shares Outstanding 355.13M | Public Float 352.94M |
| Beta 1.66 | Rev. Per Employee N/A |
| P/E Ratio 60.49 | EPS $8.00 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.33M |
ISRG Performance
| 1 Week | -5.53% | ||
| 1 Month | -18.75% | ||
| 3 Months | -14.94% | ||
| 1 Year | -18.30% | ||
| 5 Years | 87.47% |
ISRG Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
36
Full Ratings ➔
About intuitive surgical inc. - ISRG
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.
ISRG At a Glance
Intuitive Surgical, Inc.
1020 Kifer Road
Sunnyvale, California 94086-5304
| Phone | 1-408-523-2100 | Revenue | 10.06B | |
| Industry | Medical Specialties | Net Income | 2.86B | |
| Sector | Health Technology | 2025 Sales Growth | 20.505% | |
| Fiscal Year-end | 12 / 2026 | Employees | 17,021 | |
| View SEC Filings |
ISRG Valuation
| P/E Current | 60.766 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 71.925 |
| Price to Sales Ratio | 20.41 |
| Price to Book Ratio | 11.283 |
| Price to Cash Flow Ratio | 67.78 |
| Enterprise Value to EBITDA | 55.371 |
| Enterprise Value to Sales | 19.849 |
| Total Debt to Enterprise Value | 0.001 |
ISRG Efficiency
| Revenue/Employee | 591,310.734 |
| Income Per Employee | 167,792.727 |
| Receivables Turnover | 6.181 |
| Total Asset Turnover | 0.51 |
ISRG Liquidity
| Current Ratio | 4.875 |
| Quick Ratio | 3.957 |
| Cash Ratio | 2.958 |
ISRG Profitability
| Gross Margin | 65.989 |
| Operating Margin | 29.266 |
| Pretax Margin | 32.901 |
| Net Margin | 28.376 |
| Return on Assets | 14.472 |
| Return on Equity | 16.674 |
| Return on Total Capital | 15.871 |
| Return on Invested Capital | N/A |
ISRG Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 0.95 |
| Total Debt to Total Assets | 0.828 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 0.733 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Intuitive Surgical Inc. - ISRG
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 6.22B | 7.12B | 8.35B | 10.06B | |
Sales Growth
| +8.97% | +14.49% | +17.24% | +20.51% | |
Cost of Goods Sold (COGS) incl D&A
| 2.03B | 2.39B | 2.72B | 3.42B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 380.40M | 435.20M | 455.70M | 662.40M | |
Depreciation
| 326.00M | 382.00M | 439.00M | 600.00M | |
Amortization of Intangibles
| 27.80M | 20.20M | 16.70M | 13.20M | |
COGS Growth
| +14.96% | +17.68% | +13.50% | +25.95% | |
Gross Income
| 4.19B | 4.73B | 5.63B | 6.64B | |
Gross Income Growth
| +6.28% | +12.95% | +19.13% | +17.88% | |
Gross Profit Margin
| +67.30% | +66.39% | +67.46% | +65.99% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 2.61B | 2.96B | 3.29B | 3.70B | |
Research & Development
| 876.30M | 998.80M | 1.15B | 1.31B | |
Other SG&A
| 1.73B | 1.96B | 2.14B | 2.38B | |
SGA Growth
| +23.18% | +13.50% | +10.89% | +12.50% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (5.90M) | 5.00M | (33.90M) | 7.50M | |
EBIT after Unusual Expense
| 1.58B | 1.76B | 2.38B | 2.94B | |
Non Operating Income/Expense
| 23.80M | 197.10M | 291.00M | 373.40M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 1.61B | 1.96B | 2.67B | 3.31B | |
Pretax Income Growth
| -15.00% | +21.91% | +36.49% | +23.85% | |
Pretax Margin
| +25.82% | +27.50% | +32.01% | +32.90% | |
Income Tax
| 262.40M | 141.60M | 336.30M | 434.80M | |
Income Tax - Current - Domestic
| 399.60M | 348.00M | 369.80M | 294.50M | |
Income Tax - Current - Foreign
| 48.10M | 74.40M | 101.80M | 121.20M | |
Income Tax - Deferred - Domestic
| (205.20M) | (147.50M) | (181.60M) | (49.20M) | |
Income Tax - Deferred - Foreign
| 19.90M | (133.30M) | 46.30M | 68.30M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 1.34B | 1.82B | 2.34B | 2.88B | |
Minority Interest Expense
| 22.10M | 19.30M | 14.90M | 20.60M | |
Net Income
| 1.32B | 1.80B | 2.32B | 2.86B | |
Net Income Growth
| -22.43% | +35.98% | +29.18% | +22.97% | |
Net Margin Growth
| +21.25% | +25.24% | +27.81% | +28.38% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 1.32B | 1.80B | 2.32B | 2.86B | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 1.32B | 1.80B | 2.32B | 2.86B | |
EPS (Basic)
| 3.7175 | 5.1196 | 6.5388 | 8.0022 | |
EPS (Basic) Growth
| -22.34% | +37.72% | +27.72% | +22.38% | |
Basic Shares Outstanding
| 355.70M | 351.20M | 355.20M | 356.90M | |
EPS (Diluted)
| 3.6528 | 5.0308 | 6.416 | 7.8743 | |
EPS (Diluted) Growth
| -21.61% | +37.72% | +27.53% | +22.73% | |
Diluted Shares Outstanding
| 362.00M | 357.40M | 362.00M | 362.70M | |
EBITDA
| 1.96B | 2.20B | 2.80B | 3.61B | |
EBITDA Growth
| -8.44% | +12.49% | +27.37% | +28.64% | |
EBITDA Margin
| +31.46% | +30.91% | +33.58% | +35.85% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 624.407 | |
| Number of Ratings | 36 | Current Quarters Estimate | 2.126 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 10.043 | |
| Last Quarter’s Earnings | 2.53 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 8.93 | Next Fiscal Year Estimate | 11.475 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 27 | 27 | 30 | 29 |
| Mean Estimate | 2.13 | 2.48 | 10.04 | 11.48 |
| High Estimates | 2.53 | 2.66 | 10.65 | 12.37 |
| Low Estimate | 2.03 | 2.33 | 9.70 | 10.81 |
| Coefficient of Variance | 4.86 | 2.73 | 2.25 | 3.32 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 18 | 18 | 16 |
| OVERWEIGHT | 7 | 7 | 5 |
| HOLD | 9 | 8 | 11 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 1 | 1 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Intuitive Surgical Inc. - ISRG
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Intuitive Surgical Inc. - ISRG
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 29, 2026 | Gary S. Guthart Director | 28,194 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $174.26 per share | 4,913,086.44 |
| Jan 29, 2026 | Gary S. Guthart Director | 3,694 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $530.1 per share | 1,958,189.40 |
| Jan 29, 2026 | Gary S. Guthart Director | 15,720 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $531.53 per share | 8,355,651.60 |
| Jan 29, 2026 | Gary S. Guthart Director | 15,720 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $531.52 per share | 8,355,494.40 |
| Jan 29, 2026 | Gary S. Guthart Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 7, 2025 | Fredrik C. Widman VP Corporate Controller | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 7, 2025 | Fredrik C. Widman VP Corporate Controller | 2,381 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $77 per share | 183,337.00 |
| Nov 7, 2025 | Fredrik C. Widman VP Corporate Controller | 473 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $550 per share | 260,150.00 |
| Nov 7, 2025 | Fredrik C. Widman VP Corporate Controller | 473 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $550 per share | 260,150.00 |
| Nov 7, 2025 | Fredrik C. Widman VP Corporate Controller | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 7, 2025 | Fredrik C. Widman VP Corporate Controller | 632 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $59.46 per share | 37,578.72 |
| Oct 28, 2025 | David J. Rosa Chief Executive Officer (CEO); Director | 258,756 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $79.64 per share | 20,607,327.84 |
| Oct 28, 2025 | David J. Rosa Chief Executive Officer (CEO); Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | David J. Rosa Chief Executive Officer (CEO); Director | 234,256 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $547.55 per share | 128,266,872.80 |
| Oct 28, 2025 | Craig H. Barratt Director | 2,193 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $71.32 per share | 156,404.76 |
| Oct 28, 2025 | Craig H. Barratt Director | 750 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 28, 2025 | Craig H. Barratt Director | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $548.01 per share | 0.00 |
| Jul 30, 2025 | Gary S. Guthart Executive Chair of the Board o; Director | 1,204,863 | Bona fide gift | 0.00 |
| Mar 17, 2025 | Robert DeSantis EVP & Chief Strategy & Corp Op | 14,085 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $347.42 per share | 4,893,410.70 |
| Mar 17, 2025 | Robert DeSantis EVP & Chief Strategy & Corp Op | 13,488 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $498.71 per share | 6,726,600.48 |